First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction - Wikidata - wikimedia - TriplyDB

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

http://www.wikidata.org/entity/Q33795363

about

Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept.Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis †.Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.Attitudes about when and how to treat patients with AL amyloidosis: an international survey.Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.Novel pharmacotherapies for cardiac amyloidosis.New and developing therapies for AL amyloidosis.Systemic amyloidosis: novel therapies and role of biomarkers.Disease burden of systemic light-chain amyloidosis: a systematic literature review.Newer Therapies for Amyloid Cardiomyopathy.Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response News in AL Amyloidosis ASH 2016: A rapidly evolving field of investigation.Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.A Peptide-Fc Opsonin with Pan-Amyloid Reactivity Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis.Immunoglobulin Light Chains Form an Extensive and Highly Ordered Fibril Involving the N- and C-Termini.Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody.Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis.Extracellular volume with bolus-only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time.New concepts in the treatment and diagnosis of amyloidosis.Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.Serendipitous inhibition of Aβ and rVλ6Wil amyloid fibril growth by bi-functional peptides.Pretargeting immunotherapy: a novel treatment approach for systemic amyloidosis.Prognosis and risk assessment in AL amyloidosis - There and back again.Inflammation in cardiac amyloidosis: prognostic marker or therapeutic target?Antibodies to watch in 2018.Light Chain Amyloidosis.Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis The six-minute walk test in patients with AL amyloidosis: a single centre case series.A bifunctional peptide, "peptope", for pre-targeting antibody 7D8 to systemic amyloid deposits.Preliminary characterization of a novel peptide-Fc-fusion construct for targeting amyloid deposits.Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.Novel Therapies in Light Chain Amyloidosis.Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

P2860

Q36308575-CF9C64B0-0DFE-403A-9E93-B23127A1055C Q36325334-87991467-5AA9-42AB-95FF-5A42570E7572 Q36981504-A67299A7-FAAA-466E-9B80-6DF2CA2F0429 Q37494829-4E48B129-1D4E-4475-82BD-E78873FD9B30 Q37570615-B616409C-C628-4460-9625-F87F41CE279F Q38600436-DF693E8D-1474-4EBE-AFCA-2736C7544D1A Q38663987-59F1DD51-8EE5-4244-A00E-EB0E1A1524AA Q38709793-BBD10DBD-71C1-4E26-877E-5B6599AC2A47 Q38779623-45BB17D1-D577-421D-998C-35A6A5CD5E40 Q38829923-10889346-48DB-44BC-9D9D-55EC5D5E4B37 Q38917828-29DA91F9-1A82-46CA-A930-A7A544258C5A Q38920614-7B076CED-5511-4CED-82E3-D243E79186AE Q38928383-03AD05D9-E75D-46C3-93C5-8C0985211B40 Q38959241-AABE63F2-2611-4159-A8B8-B068D50EB94B Q39272596-B6D8EC9F-E37E-446B-9DCE-7B1451872328 Q39446111-5AE25A16-B305-40AD-9B71-5AB665193AEF Q40261261-0008F675-50A2-4A99-B1FB-039EADE51E76 Q40362742-162A2BBA-4A47-4070-A74C-74D295541C04 Q41471564-5A65B9C0-05CA-479B-9788-B6C452BC9A3C Q42292795-2AE7E246-1DDE-49A8-B393-145A18EDABD1 Q42319096-53BADD97-CEA2-4866-9B09-599FD11002FC Q42360535-A3C1966D-4741-459D-A2DC-A8B11C50FB63 Q46463218-74DF6845-1AD9-408E-B460-F8901BF6C45B Q47404960-FFB06A00-5F6C-45D6-A923-18002CF65E45 Q47437226-31025DAB-9A7D-4E0F-872C-EC113607B99F Q47561519-E4FA8BF9-074D-482C-B7C2-9BDB875C9C60 Q47643557-C474BAE5-CA8B-4396-AA7D-FA59EEDD4D5C Q47875858-52FE0BF2-FAB3-4692-834B-D837DB20F727 Q47927900-9C2AE222-D2CD-49F9-B3CC-8702E4E9A44C Q48239985-02CCC35B-C45E-404E-BAA7-35D1E1045B10 Q49932643-8D862B10-D53D-42C1-83F0-1E4B5E621079 Q50120289-1A56B604-023B-4233-9703-33961BD5C9F7 Q52659305-235F25C2-CDE6-4CB7-9840-F11F0D0552BE Q52716575-767BB350-7D54-4E32-9A88-71F52FD332D0 Q53402595-4A57CF7E-0131-4B70-8EFD-863E32E46B35 Q54104536-8C4A1E31-5496-4967-8D13-67CC8591E283 Q54537223-8DFEF6C6-D8FB-4AC7-991C-973BD5307523 Q55023498-57823649-8678-4230-BF72-8A5F5A1F3D51 Q55127439-108A0304-39F4-44DD-9E65-F61EDE5B624D Q55177621-2EA6BDDC-1037-44AA-B866-2ECB1100A676

P2860

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

http://www.wikidata.org/entity/Q33795363

description

2016 nî lūn-bûn

@nan

2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

First-in-Human Phase I/II Stud ...... d Persistent Organ Dysfunction

@ast

First-in-Human Phase I/II Stud ...... d Persistent Organ Dysfunction

@en

type

label

First-in-Human Phase I/II Stud ...... d Persistent Organ Dysfunction

@ast

First-in-Human Phase I/II Stud ...... d Persistent Organ Dysfunction

@en

prefLabel

First-in-Human Phase I/II Stud ...... d Persistent Organ Dysfunction

@ast

First-in-Human Phase I/II Stud ...... d Persistent Organ Dysfunction

@en

P1433

Q33795363-134387E3-6AE5-402D-9913-15C7701F3897

P1476

Q33795363-ACDAD54F-A3A5-4A6E-A453-7F95DE268950

P2093

Q33795363-3132AA72-8015-4F91-A34E-0830FD757AEF

Q33795363-3AB0393B-D175-4DC7-9F35-416C8FAF0101

Q33795363-497859C1-A1E1-4D8E-85A9-8742F97FB452

Q33795363-4DE4EC36-A240-4342-9885-98223A05F4E4

Q33795363-4E8BA8DD-FDA3-4E99-A891-CE2F8BD3042F

Q33795363-53DDA143-7C75-4EC3-B7FA-C65D1EAB136F

Q33795363-58D2E904-D3DF-4A82-9847-8EE77BCAFDDC

Q33795363-8325F953-D9D9-4929-802A-2567DDCE4C51

Q33795363-88987BF5-644F-4C54-940E-D18A647DB3A7

Q33795363-98E1E8C2-0D34-4FA0-9800-863AC8542A26

P2860

Q33795363-03784E16-8A27-4615-B62D-C42AA2304258

Q33795363-07AE9E5A-E065-4C5E-86C5-2DDCA31277F3

Q33795363-15993EE3-4D6C-498A-A9C8-A8D56AE9A8EA

Q33795363-1AB92C11-08ED-40BB-BE45-0724461FA28A

Q33795363-2B4A4431-3590-452E-A97C-24BC262C8388

Q33795363-2D116240-8EDD-42F5-9CD3-839DD8864C7E

Q33795363-30E0FF5E-5C85-4794-A69B-BD8EFCE82017

Q33795363-430A9783-4615-43B2-9ED0-467A06362223

Q33795363-46CE3CF7-941F-4EEB-AA78-FA254F57C661

Q33795363-4B75A459-66B8-406C-AB41-222DB941F7E4

P304

Q33795363-C438D5A5-09B0-417A-8915-525346BFC0F0

P31

Q33795363-8B70B49D-DA6F-467E-977D-0624B7BC877C

P356

Q33795363-B41161F5-4737-44B2-A6A9-6DAF06365498

P407

Q33795363-B6673115-3705-4A80-B484-C361EA78D698

P433

Q33795363-59DB35A8-B855-4939-94CE-F4FB174A06EC

P478

Q33795363-076EA40F-9116-4326-BB9F-E15AB772B8CD

P50

Q33795363-7DCD224D-A423-4845-B24D-D4F86336F621

Q33795363-B556E49D-13BF-4825-B76C-3B868E9F13D9

Q33795363-E2456AD0-06E3-46B7-9538-8EFF9D655F54

P577

Q33795363-1F758395-CC1B-49A0-A6C1-BA54E220C445

P698

Q33795363-8F7D2999-C93C-4A31-A704-2F568F84D281

P932

Q33795363-00CD22FD-74FE-449E-BD69-7593594E3A23

P356

JCO.2015.63.6530

P1433

Journal of Clinical Oncology

P1476

First-in-Human Phase I/II Stud ...... d Persistent Organ Dysfunction

@en

P2093

Brendan Weiss

http://www.w3.org/2001/XMLSchema#string

Dale B Schenk

http://www.w3.org/2001/XMLSchema#string

David Seldin

http://www.w3.org/2001/XMLSchema#string

Gene G Kinney

http://www.w3.org/2001/XMLSchema#string

Heather Landau

http://www.w3.org/2001/XMLSchema#string

Jackie Walling

http://www.w3.org/2001/XMLSchema#string

Jeffrey Zonder

http://www.w3.org/2001/XMLSchema#string

Martin Koller

http://www.w3.org/2001/XMLSchema#string

Michaela Liedtke

http://www.w3.org/2001/XMLSchema#string

Raymond L Comenzo

http://www.w3.org/2001/XMLSchema#string

P2860

Update on treatment of light chain amyloidosis

Light-chain (AL) amyloidosis: diagnosis and treatment.

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.

AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils.

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.

Amyloidosis: pathogenesis and new therapeutic options.

Persistent lung inflammation and fibrosis in serum amyloid P component (APCs-/-) knockout mice

Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

P304

1097-1103

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2015.63.6530

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

Giampaolo Merlini

Stefan Schönland

P577

2016-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26858336

http://www.w3.org/2001/XMLSchema#string

P932

5470113

http://www.w3.org/2001/XMLSchema#string